Freespira is indicated (FDA-cleared) as an adjunctive treatment of symptoms associated with panic disorder, panic attacks and/or PTSD in patients 18 and older.
Product Description
Freespira is indicated (FDA-cleared) as an adjunctive treatment of symptoms associated with panic disorder, panic attacks and/or PTSD in patients 18 and older. In younger patients, Freespira has been evaluated and is being made available as permitted by FDA’s COVID-19 Enforcement Discretion Guidance.
Premium Content
You need a “Digital Health (Premium)” subscription to view:
Clinical Monograph
Formulary Coverage
Pipeline
Need a subscription? Subscribe
Twitter feed is not available at the moment.